A facile and efficient visible-light-driven method has been developed to construct sulfoxides via oxidative coupling of aryldiazo sulfones with thiolsusing the O2 in air as the oxidant. This reaction could be performed at room temperature under catalyst- and additive-free conditions. The present methodology offers a mild and environmentally benign approach to obtain a library of sulfoxides in good
Transition-Metal-Free Arylations of In-Situ Generated Sulfenates with Diaryliodonium Salts
作者:Hao Yu、Zhen Li、Carsten Bolm
DOI:10.1021/acs.orglett.8b03046
日期:2018.11.16
A transition-metal-free arylation of sulfenate anions generated from β-sulfinyl esters with diaryliodoniumsalts was developed. In this process, a new C–S bond is formed under mild reaction conditions providing a wide range of S,S-diaryl and S-alkyl S-aryl sulfoxides.
Sulfoxide and Sulfone Synthesis via Electrochemical Oxidation of Sulfides
作者:Jin Kyu Park、Sunwoo Lee
DOI:10.1021/acs.joc.1c01657
日期:2021.10.1
sulfides to the corresponding sulfoxides and sulfones under electrochemical conditions is reported. Sulfoxides are selectively obtained in good yield under a constant current of 5 mA for 10 h in DMF, while sulfones are formed as the major product under a constant current of 10 or 20 mA for 10 h in MeOH. The oxygen of both the sulfoxide and sulfone function is derivedfrom water.
报道了在电化学条件下二芳基硫化物和芳基烷基硫化物氧化成相应的亚砜和砜。在 DMF 中,5 mA 恒定电流下 10 小时选择性地获得亚砜,而在 MeOH 中,10 或 20 mA 恒定电流下 10 小时形成的主要产物是砜。亚砜和砜官能团的氧均来自水。
Caspase inhibitors and uses thereof
申请人:Diu-Hercend Anita
公开号:US20070010457A1
公开(公告)日:2007-01-11
The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-(“IL-1”), apoptosis-, interferon-y inducing factor-(IGIF), interferon-γ-(“IFN-γ”), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-γ production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-γ-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.